-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Vericel (NASDAQ:VCEL) Versus Allena Pharmaceuticals (NASDAQ:ALNAQ) Financial Analysis
Vericel (NASDAQ:VCEL) Versus Allena Pharmaceuticals (NASDAQ:ALNAQ) Financial Analysis
Vericel (NASDAQ:VCEL – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
Profitability
This table compares Vericel and Allena Pharmaceuticals' net margins, return on equity and return on assets.
Get Vericel alerts:Net Margins | Return on Equity | Return on Assets | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Risk and Volatility
Vericel has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Institutional & Insider Ownership
7.3% of Allena Pharmaceuticals shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 3.7% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.Valuation & Earnings
This table compares Vericel and Allena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vericel | $156.18 million | 7.19 | -$7.47 million | ($0.39) | -61.03 |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Vericel has higher revenue and earnings than Allena Pharmaceuticals.
Analyst Ratings
This is a summary of recent recommendations and price targets for Vericel and Allena Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Vericel presently has a consensus price target of $37.40, suggesting a potential upside of 57.14%. Given Vericel's higher possible upside, equities research analysts clearly believe Vericel is more favorable than Allena Pharmaceuticals.
Summary
Vericel beats Allena Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About Vericel
(Get Rating)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
Vericel (NASDAQ:VCEL – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
威瑞塞爾(納斯達克:VCEL-GET評級)和艾琳娜製藥(納斯達克:ALNAQ-GET評級)都是小盤醫療公司,但哪一家更好?我們將根據這兩家公司的收益、機構持股、股息、分析師建議、盈利能力、估值和風險等方面的實力進行比較。
Profitability
盈利能力
This table compares Vericel and Allena Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了Vericel和Allena製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
淨利潤率 | 股本回報率 | 資產回報率 | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena製藥公司 | 不適用 | -287.46% | -146.58% |
Risk and Volatility
風險和波動性
Vericel has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Vericel的貝塔係數為1.99,這表明其股價的波動性比標準普爾500指數高出99%。相比之下,Allena PharmPharmticals的貝塔係數為1.36,這表明其股價的波動性比標準普爾500指數高36%。
Institutional & Insider Ownership
機構與內部人持股
Valuation & Earnings
估值與收益
This table compares Vericel and Allena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
該表格比較了Vericel和Allena PharmPharmticals的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vericel | $156.18 million | 7.19 | -$7.47 million | ($0.39) | -61.03 |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
Vericel | 1.5618億美元 | 7.19 | -747萬美元 | ($0.39) | -61.03 |
Allena製藥公司 | 不適用 | 不適用 | -4,866萬元 | 不適用 | 不適用 |
Vericel has higher revenue and earnings than Allena Pharmaceuticals.
Vericel的收入和收益高於Allena製藥公司。
Analyst Ratings
分析師評級
This is a summary of recent recommendations and price targets for Vericel and Allena Pharmaceuticals, as provided by MarketBeat.
這是MarketBeat提供的Vericel和Allena製藥公司最近的建議和目標價摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena製藥公司 | 0 | 0 | 0 | 0 | 不適用 |
Vericel presently has a consensus price target of $37.40, suggesting a potential upside of 57.14%. Given Vericel's higher possible upside, equities research analysts clearly believe Vericel is more favorable than Allena Pharmaceuticals.
Vericel目前的共識目標價為37.40美元,這意味着潛在的上行空間為57.14%。考慮到Vericel更有可能的上行空間,股票研究分析師顯然認為Vericel比Allena PharmPharmticals更有利。
Summary
摘要
Vericel beats Allena Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
Vericel在兩隻股票比較的10個因素中有8個擊敗了Allena PharmPharmticals。
About Vericel
關於Vericel
(Get Rating)
(獲取評級)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel公司是一家商業階段的生物製藥公司,在美國從事運動醫學和嚴重燒傷護理市場的細胞療法的研究、開發、製造和分銷。該公司銷售自體細胞治療產品,包括用於修復有症狀的膝部單個或多個全層軟骨缺陷的自體細胞化支架產品Maci,以及用於治療成人和兒童深真皮或全面燒傷患者的永久性皮膚置換人道主義使用設備Epicel。其預批准階段的產品是NexoBrid,這是一種註冊階段的生物孤兒產品,用於治療成人深度部分和/或全層熱燒傷的焦痂去除。該公司前身為阿斯特羅姆生物科學公司。Vericel公司成立於1989年,總部設在馬薩諸塞州劍橋市。
About Allena Pharmaceuticals
關於Allena製藥公司
(Get Rating)
(獲取評級)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Allena製藥公司是一家生物製藥公司,在美國發現、開發和商業化口服酶療法,用於治療罕見和嚴重的代謝以及腎臟疾病患者。它的主要候選產品是ALLN-346,這是一種新型的尿酸降解酶,適用於晚期慢性腎臟疾病中的高尿酸血癥和痛風患者。該公司成立於2011年,總部設在馬薩諸塞州牛頓市。2022年9月2日,Allena製藥公司根據破產法第11章向美國特拉華州地區破產法院提交了自願重組請願書。
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vericel Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vericel和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧